



Zelda Therapeutics Ltd
ACN 103 782 378
www.zeldatherapeutics.com
Level 45
108 St Georges Terrace,
Perth Western Australia 6000

16 December 2016

COMPANY SECRETARY APPOINTMENT

The Board of Zelda Therapeutics Ltd (ASX: ZLD) is pleased to announce the appointment Mr Tim Slate as Company Secretary of the Company with immediate effect.

Mr. Slate has a Bachelor of Commerce from the University of Western Australian, is a Chartered Accountant and is an Associate Member of the Governance Institute of Australia. Mr. Slate provides accounting and secretarial advice to private and public companies. Mr Slate has nine years' experience in chartered accounting.

Zelda would like to thank Mr Neville Basset who has retired as Company Secretary.

CONTACTS

Corporate
Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors
Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Media
Andrew Ramadge
Media & Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (Aunt Zelda's) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has been granted a worldwide, exclusive and perpetual licence to this data, related systems, formulations and treatment protocols. Zelda will use this information to design a series of human clinical trials that have a high probability of success given the existing patient data and experiences it has access to.

In addition, Zelda has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry.